‘Kerendia,’ a treatment for chronic kidney disease, is now available for prescription after receiving approval for insurance reimbursement.

According to industry sources, Bayer’s Kerendia (finerenone) has passed the drug committee (DC) of Big 5 tertiary general hospitals, including Seoul National University, Seoul Asan Hospital, and Sinchon Severance Hospital. Additionally, 49 hospitals in Korea have assigned Kerendia’s prescription code.

Kerendia is a treatment for chronic kidney disease accompanying type 2 diabetes. It has been listed for reimbursement since February last year.

With Chon Kun Dang becoming a marketing partner in South Korea, rapid landing and